ADXS plans to submit 2H17 MAA for AXAL in metastatic cervical cancer (consistent with prior guidance): http://finance.yahoo.com/news/ema-certification-paves-way-maa-120000615.html The MAA will be based on phase-2 data and it should be considered a longshot for marketing approval, IMO.